Risk of adverse behavioral effects with pediatric use of antidepressants.
about
Pharmacotherapy for anxiety disorders in children and adolescentsDevelopment and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment ProfileAnimal models of suicide-trait-related behaviorsActivation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCDPerinatal citalopram exposure selectively increases locus ceruleus circuit function in male rats.Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disordersPharmacotherapy for Pediatric Generalized Anxiety Disorder: A Systematic Evaluation of Efficacy, Safety and TolerabilitySSRI adverse events: how to monitor and manage.Suicidal events in the Treatment for Adolescents With Depression Study (TADS).Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention.Intensive Family-Based Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder: Applications for Treatment of Medication Partial- or Nonresponders.The nature, assessment, and treatment of obsessive-compulsive disorder.Towards translational rodent models of depression.Common Factors in Pediatric Psychiatry: A Review of Essential and Adjunctive Mechanisms of Treatment Outcome.Paroxetine-induced increase in activity of locus coeruleus neurons in adolescent rats: implication of a countertherapeutic effect of an antidepressant.Behavioral destabilization induced by the selective serotonin reuptake inhibitor fluoxetine.The role of co-occurring disruptive behavior in the clinical presentation of children and adolescents with anxiety in the context of autism spectrum disorders.
P2860
Q24239941-07D1B305-185E-4C50-9BCE-862DC69EE318Q24623483-FB0F774A-13F7-48D6-885E-0FC852B56F2EQ24645693-190C2601-9BF1-4A19-A9A7-D63543494F49Q33799525-1C0F7BA8-A781-4A3E-9DAF-8A099EE0F31DQ34303518-859AAFE6-AAD3-420B-BA0D-2A2A7FA7A879Q35853507-21FDFBA9-BD26-423A-9880-63DE2B2C9D2DQ36873932-4F61779F-5DD1-4049-B105-0618C8E4D6B4Q37047635-F77CC321-11A4-43F3-9F75-4E3472277CC9Q37127462-99213073-9764-4324-9FB4-CCFF6AC5C524Q37243110-54D4C125-A814-4F31-8B06-FD266219FF35Q37257029-0D474F16-9337-47FE-B9BD-F8E9439FC70FQ37257042-523B376C-0DD9-44BD-AB64-7074CAE4B2D7Q37982217-60B7F0C5-F986-4331-BFD1-BB1A01027351Q38092709-50393BBC-9F4A-45B5-9928-FF245A924ED6Q38820952-F7F6E10D-C779-44AD-AA81-33CE9A81591FQ41204358-55C48E68-1103-4304-A85A-96FC8B00CA9FQ41909614-0CDA09D8-FB07-4337-8222-3FFD6E67B686Q50308130-D7E533EA-D566-4677-BD0D-18A22FC81277
P2860
Risk of adverse behavioral effects with pediatric use of antidepressants.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Risk of adverse behavioral effects with pediatric use of antidepressants.
@ast
Risk of adverse behavioral effects with pediatric use of antidepressants.
@en
Risk of adverse behavioral effects with pediatric use of antidepressants.
@nl
type
label
Risk of adverse behavioral effects with pediatric use of antidepressants.
@ast
Risk of adverse behavioral effects with pediatric use of antidepressants.
@en
Risk of adverse behavioral effects with pediatric use of antidepressants.
@nl
prefLabel
Risk of adverse behavioral effects with pediatric use of antidepressants.
@ast
Risk of adverse behavioral effects with pediatric use of antidepressants.
@en
Risk of adverse behavioral effects with pediatric use of antidepressants.
@nl
P2093
P2860
P1433
P1476
Risk of adverse behavioral effects with pediatric use of antidepressants.
@en
P2093
Eric A Storch
Tanya K Murphy
Wayne K Goodman
P2860
P2888
P356
10.1007/S00213-006-0642-6
P577
2006-12-19T00:00:00Z
P6179
1005542639